Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
36.36%
Operating Margin
15.01%
Net Margin
9.68%
Efficiency Metrics
Revenue per Expense Ratio
1.18
R&D as % of Revenue
3.54%
Earnings Quality
EBITDA Margin
22.46%
Income Tax Rate
30.44%
EPS
3.5600000000
Balance Sheet Analysis
Current Ratio
3.53
Cash Ratio
0.70
Working Capital
$629.29M
Debt to Equity
0.54
Debt to Assets
28.06%
Equity Ratio
52.39%
Cash Flow Analysis
Operating Cash Flow Ratio
12.90%
Free Cash Flow Ratio
5.54%
CapEx to Revenue
7.36%
Dividends Paid
$31.16M
Stock Buybacks
$3.14M
Total Shareholder Returns
$34.30M
Cash Position Change
-40.56%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 18.39%
Increased R&D investment by 1.72%
Detailed Growth Metrics
Core Performance
Revenue
10.92%
Net Income
16.04%
EPS
16.34%
Operating Income
-4.79%
Operational Efficiency
R&D Expenses
1.72%
SG&A Expenses
21.14%
Operating Cash Flow
15.48%
Free Cash Flow
99.67%
Balance Sheet Health
Assets
11.74%
Debt
15.72%
Book Value per Share
12.10%
Inventory
21.95%
Shareholder Returns
Dividends per Share
18.39%
Shares Outstanding
-0.54%
Long Term Trends
3Y Revenue/Share
32.19%
5Y Revenue/Share
20.89%
3Y Dividend/Share
31.56%
5Y Dividend/Share
47.06%